Shuttle Pharmaceuticals Holdings, Inc. announced the issuance of various unregistered equity securities following stockholder approval obtained at a Special Meeting on September 9, 2026. The issuances include over 3.7 million shares of common stock from the conversion of preferred shares, as well as new common stock purchase warrants and pre-funded warrants.
Key Details
- Common Stock Issuance: As of September 14, 2026, the company issued an aggregate of 3,737,482 shares of common stock upon the conversion of its Series B-1 (2,869,595 shares) and Series B-2 (867,887 shares) Preferred Stock.
- New Warrants: Effective September 9, 2026, the company issued common stock purchase warrants to acquire approximately 927,114 shares. These warrants have a three-year term and an exercise price of $10.30 per share.
- Pre-Funded Warrants: The company also issued pre-funded warrants to acquire approximately 16,932,508 shares of common stock as of September 9, 2026.
- Regulatory Exemption: All securities were issued without registration under the Securities Act of 1933, in reliance upon the exemption provided by Section 4(a)(2).